The partnership will see Abbott’s new CGM sensor, developed based on its FreeStyle Libre technology, exclusively integrated with Medtronic’s AID algorithms. This integration will allow for automatic insulin adjustments, aiding people with diabetes in maintaining better glucose control.
Targeting over 11 million people worldwide who rely on multiple daily insulin injections to manage their Type 1 or Type 2 diabetes, the collaboration aims to combine Abbott’s leading CGM technology with Medtronic’s expertise in insulin delivery. The goal is to enhance the lives of millions of people living with diabetes by providing a more streamlined and effective management system.
Though the financial terms of the partnership were not disclosed, it is expected to strengthen both companies’ positions in the diabetes care market.
“This partnership pairs two global leaders in glucose sensing technology and insulin delivery,” said Jared Watkin, executive vice president of Abbott’s diabetes care business. “Libre technology has set the standard for accurate, accessible, easy-to-use, and reliable continuous glucose monitoring. Connecting this CGM built for Medtronic’s insulin delivery systems and algorithms makes it easier for people to spend less time thinking about their diabetes and more time living.”
The integration of Abbott’s advanced CGM technology with Medtronic’s insulin delivery systems represents a significant step forward in diabetes care. This collaboration highlights the ongoing efforts to innovate and improve the quality of life for those managing diabetes.
Related topics:
UAB Startup TIXiMED Secures FDA Clearance for Novel Oral Type 1 Diabetes Drug
AIIMS Unveils New Diabetes Care Software for Remote Health Centres
